Table 1.
Baseline demographics and disease characteristics
| Characteristic | Melanoma |
NSCLC |
UC |
RCC |
Total |
|---|---|---|---|---|---|
| (n = 35) | (n = 23) | (n = 29) | (n = 34) | (N = 121)a | |
| Age, median (range), years | 69 (38-92) | 69 (50-87) | 72 (54-88) | 66.5 (48-87) | 70 (38-92) |
| ≥65 | 21 (60.0) | 14 (60.9) | 23 (79.3) | 19 (55.9) | 77 (63.6) |
| ≥75 | 15 (42.9) | 4 (17.4) | 11 (37.9) | 7 (20.6) | 37 (30.6) |
| Sex, n (%) | |||||
| Men | 15 (42.9) | 16 (69.6) | 25 (86.2) | 24 (70.6) | 80 (66.1) |
| Women | 20 (57.1) | 7 (30.4) | 4 (13.8) | 10 (29.4) | 41 (33.9) |
| Race, n (%) | |||||
| White | 35 (100.0) | 22 (95.7) | 20 (69.0) | 33 (97.1) | 110 (90.9) |
| Asian | 0 | 1 (4.3) | 0 | 0 | 1 (0.8) |
| Otherb | 0 | 0 | 6 (20.7) | 0 | 6 (5.0) |
| Missing | 0 | 0 | 3 (10.3) | 1 (2.9) | 4 (3.3) |
| ECOG PS, n (%) | |||||
| 0 | 14 (40.0) | 3 (13.0) | 11 (37.9) | 17 (50.0) | — |
| 1 | 21 (60.0) | 20 (87.0) | 18 (62.1) | 17 (50.0) | — |
| Median time since initial diagnosis (range), months | 22.1 (1.0-240.8) | 2.5 (0.7-6.4) | 14.2 (4.8-92.7) | 8.6 (1.0-266.6) | — |
| Median time since unresectable/metastatic diagnosis (range), months | 1.94 (0.5-138.8) | 1.8 (0.2-4.9) | 3.9 (0.5-46.5) | 2.6 (0.5-40.0) | — |
| Prior systemic therapy, n (%) | 11 (31.4) | 1 (4.3) | 24 (82.8) | 0 | 36 (29.8) |
| 1 line | 7 (20.0) | 0 | 15 (51.7) | 0 | 22 (18.2) |
| 2 lines | 2 (5.7) | 1 (4.3) | 9 (31.0) | 0 | 12 (9.9) |
| ≥2 lines | 2 (5.7) | 0 | 0 | 0 | 2 (1.7) |
| Prior radiotherapy, n (%)c | 4 (11.4) | 6 (26.1) | 4 (13.8) | 4 (11.8) | 18 (14.9) |
| Prior surgery, n (%) | 29 (82.9) | 5 (21.7) | 26 (89.7) | 26 (76.5) | 86 (71.1) |
| Histology at baseline, n (%) | |||||
| Cutaneous | 30 (85.7) | — | — | — | 30 (24.8) |
| Acral | 1 (2.9) | — | — | — | 1 (0.8) |
| Adenocarcinoma | — | 15 (65.2) | 12 (41.4) | — | 27 (22.3) |
| Large cell carcinoma | — | 1 (4.3) | — | — | 1 (0.8) |
| Squamous | — | 7 (30.4) | 1 (3.4) | — | 8 (6.6) |
| Transitional cell | — | — | 12 (41.4) | — | 12 (9.9) |
| Clear cell | — | — | — | 31 (91.2) | 31 (25.6) |
| Clear cell with other component | — | — | — | 3 (8.8) | 3 (2.5) |
| Other | 4 (11.4)d | 0 | 4 (13.8)e | 0 | 8 (6.6) |
| Stage at baseline, n (%) | |||||
| Stage 2A | 1 (2.9) | — | — | — | — |
| Stage 3 | — | — | — | 3 (8.8) | — |
| Stage 3A | 1 (2.9) | — | — | — | — |
| Stage 3B | 1 (2.9) | — | — | — | — |
| Stage 3C | 3 (8.6) | — | — | — | — |
| Stage 4 | 29 (82.9) | — | 23 (79.3) | 31 (91.2) | — |
| Stage 4A | — | 16 (69.6) | 1 (3.4) | — | — |
| Stage 4B | — | 7 (30.4) | 5 (17.2) | — | — |
Data cut-off date: 15 April 2021.
ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma; UC, urothelial carcinoma.
a
Enrolled at 34 study sites: 24 in Romania, 23 in France, 19 in Italy, 17 in the United States, 11 in Spain, 10 in Hungary, 9 in Poland, and 8 in Austria.
b
Other includes not applicable/not available/not specified/not reported for patients in France.
c
Includes patients who received neoadjuvant, adjuvant, or palliative radiotherapy.
d
Two patients had mucosal, one had nodular, and one had superficial spreading melanoma.
e
Two patients had UC (not otherwise specified), one had epidermoid, and one had papillary UC.